Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 14/20 | 0.60 |
| ▸ | EGFR | P00533 | 13/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14026424 | 0.93 | ERBB2 (0.52) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL4169796 | 0.88 | ERBB2 (0.60) | ERBB2EGFRLCKEPHA2EPHB4 | |
| SCHEMBL5568819 | 0.85 | EGFR (0.62) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL12205209 | 0.85 | EGFR (0.60) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL30126431 | 0.81 | ERBB2 (0.60) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL30125852 | 0.81 | ERBB2 (0.60) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL30126786 | 0.81 | ERBB2 (0.60) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL30127080 | 0.81 | ERBB2 (0.60) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL12205099 | 0.81 | EGFR (0.62) | ERBB2EGFRLCKAURKARPS6KB1 | |
| SCHEMBL2487588 | 0.81 | ERBB2 (0.59) | ERBB2EGFRLCKAURKARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174273-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210284656-A9 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-20190161500-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-05-30 | — | — | US | disclosed |
| US-10221194-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221194-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170260202-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260202-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9676791-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676791-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9527865-B2 | — | — | 2016-12-27 | — | — | US | disclosed |
| US-20090048279-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048279-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048279-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1660090-A4 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7452895-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452895-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452895-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1660090-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043334-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005016346-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221194-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, FLT3, RET | ERBB2 7/4885EGFR 4/4885LCK 52/4885 |
| US-20090048279-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | ERBB2 2/4885EGFR 6/4885LCK 32/4885 |
| US-20210284656-A9 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, ERBB4 | ERBB2 2/4885EGFR 4/4885LCK 24/4885 |
| US-11174273-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, ERBB4 | ERBB2 2/4885EGFR 4/4885LCK 24/4885 |
| US-20190161500-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, ERBB4 | ERBB2 2/4885EGFR 4/4885LCK 24/4885 |
| US-20170260202-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | ERBB2 2/4885EGFR 4/4885LCK 21/4885 |
| US-20050043334-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | ERBB2 2/4885EGFR 6/4885LCK 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.